Public market insider buying at VBI Vaccines (VBV)

Public market insider buying at VBI Vaccines (T:VBV)

Jeffrey Royston Baxter, a Senior Officer and Director, acquired 144,000 Common Shares on a direct ownership basis at a price of $0.732 on June 19th, 2019. This represents a $105,336 investment into the company's shares and an account share holdings change of 45.8%.

Nell Beattie, a Senior Officer, acquired 8,000 Common Shares on a direct ownership basis at a price of $0.736USD on June 19th, 2019. This represents a $7,853 investment into the company's shares and an account share holdings change of 19.0%.

VBI Vaccines is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

VBI Vaccines Inc. is a development-stage biotechnology company. The Company's principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company's subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).